Xtant Medical (NYSEAMERICAN:XTNT) Shares Pass Below 200-Day Moving Average – Should You Sell?

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.56 and traded as low as $0.4195. Xtant Medical shares last traded at $0.4195, with a volume of 15,119 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Craig Hallum reaffirmed a “buy” rating on shares of Xtant Medical in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $1.00 price objective on shares of Xtant Medical in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $1.00.

Xtant Medical Price Performance

The stock has a market cap of $58.84 million, a price-to-earnings ratio of 41.99 and a beta of -0.16. The company has a 50-day simple moving average of $0.47 and a two-hundred day simple moving average of $0.56. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.64 and a current ratio of 3.34.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $20.88 million for the quarter, compared to analysts’ expectations of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Xtant Medical in the 2nd quarter valued at about $26,000. Tradition Wealth Management LLC acquired a new position in Xtant Medical during the fourth quarter worth approximately $79,000. Wiregrass Investment Management LLC acquired a new position in Xtant Medical during the fourth quarter worth approximately $81,000. Mink Brook Asset Management LLC raised its stake in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in Xtant Medical in the fourth quarter valued at approximately $220,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.